1. ESSENCE trial: Phase III clinical trial on once-weekly semaglutide for metabolic dysfunction–associated steatohepatitis with liver fibrosis.
2. Positive treatment effects: including resolution of steatohepatitis, reduction in liver fibrosis, weight loss, and beneficial impact on glycemia and insulin resistance.
3. Safety profile: Gastrointestinal adverse events more common with semaglutide, but similar incidence of serious adverse events between groups.
4. Limited treatment options: Potential significance of once-weekly semaglutide in the context of limited treatment options for metabolic dysfunction–associated steatohepatitis.
5. Future trial focus: Ongoing trial to assess effects on clinical outcomes, including cirrhosis-free survival.

Source: The New England Journal of Medicine